Trial Profile
A Phase II Study of INVAC-1 as Treatment of Patients With High-risk Chronic Lymphocytic Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs HTERT DNA vaccine Invectys (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Invectys
- 06 Jul 2020 Status changed from recruiting to discontinued. According to ClinicalTrials.gov: US National Institutes of Health record, this trial has been discontinued. Reason: sponsor decision.
- 09 Sep 2019 According to a Personalis media release, the company announced that it has entered into a research agreement with Invectys. Personalis will provide comprehensive tumor immunogenomics capabilities to facilitate biomarker discovery in chronic lymphocytic leukemia (CLL) patients enrolled in this study.
- 12 Jul 2019 Planned number of patients changed from 84 to 90.